Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.

Inclusion Criteria: * Adults (≥18 years) with diabetes * DME in the study eye (if both eyes have DME both eyes will be included in analysis) * BCVA minimum of 20/200 (35 letters) * Central Macular Thickness (CMT) ≥300 µm * Patients with DME who were treated with Ozurdex at least twice (baseline is before the first Ozurdex injection). * Follow up of at least 6 months after the last Ozurdex injection given * Complete records including BCVA (OCT and Fluorescein Angiography (FA) if available) throughout the follow up Exclusion Criteria: * Patients with ME not secondary to Diabetes Mellitus (DM). * Presence of other retinopathies (AMD, RVO) or visually significant ocular morbidity (e.g. advanced glaucoma, corneal opacity) * Previous ocular trauma or surgery other than cataract extraction * Intravitreal triamcinolone ≤6 months before baseline * Intravitreal bevacizumab, ranibizumab, or pegaptanib \<1 months before baseline * Marked intraocular pressure (IOP) elevation in response to any previous steroid treatment * Ocular Hypertension (OHT) in the study eye(s) * IOP \>23 mm Hg without antiglaucoma medication * IOP \>21 mm Hg with one antiglaucoma medication * Use of 2 or more antiglaucoma medications * Glaucoma - Visual Fields (VF) defect \> 4 dB